Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology | Endocrinology | Family Medicine

Clinical Trials: Pancreatic Cancer


A listing of clinical trials currently looking for volunteers to enroll in Pancreatic Cancer studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Birmingham : Birmingham Hematology and Oncology Associates, LLC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Birmingham : University of Alabama Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Mobile : University of South Alabama Mitchell Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Mobile : University of South Alabama Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Arizona

Gilbert : Banner Healthcare

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Scottsdale : Scottsdale Healthcare

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Tucson : Arizona Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Arkansas

Little Rock : University of Arkansas for Medical Sciences Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

California

Bellflower : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Duarte : City of Hope

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer

Duarte : City of Hope

Clinical Value of Molecular Profiling of Pancreatic Cancer Surgical Patients

Duarte : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Encinitas : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Los Angeles : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Orange : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

San Francisco : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Santa Maria : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Alhambra : Central Hematology Oncology Medical Group, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Bakersfield : Comprehensive Blood and Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Duarte : City of Hope National Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Fresno : California Cancer Associates for Research and Excellence (CCARE)

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Long Beach : Pacific Shores Medical Group

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Los Angeles : UCLA Community Oncology Practice

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Los Angeles : Cedars-Sinai Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Orange : Hematology Oncology Medical Group of Orange County, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Palo Alto : Stanford University Medical Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Palo Alto : Stanford Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Rancho Cucamonga : Wilshire Oncology Medical Group, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Sacramento : Sutter Institute for Medical Research Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

San Diego : Sharp Health Care

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

San Francisco : California Pacific Medical Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

San Francisco : California Pacific Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

San Jose : San Jose Medical Group

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Colorado

Aurora : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Aurora : University of Colorado Denver

Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

Aurora : University of Colorado Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Grand Junction : Saint Mary's Regional Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Connecticut

Stamford : Hematology Oncology Associates, PC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Stamford : Stamford Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Delaware

Newark : Christiana Care Health Services Helen Graham Cancer Center

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

District of Columbia

Florida

Boynton Beach : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Tampa : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Boca Raton : Boca Raton Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Gainesville : University of Florida Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Jacksonville : Mayo Clinic Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Lakeland : Lakeland Regional Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Tampa : Florida Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Tampa : MOFFITT Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Tampa : USF Tampa General Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

Georgia

Atlanta : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Savannah : Memorial University Medical Center

ACOSOG Z5041 : A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma.

Savannah : Memorial University Medical Center

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

View More »

Atlanta : Georgia Cancer Specialists, P.C.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Illinois

Chicago : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Chicago : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Arlington Heights : Illinois Cancer Specialists Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Chicago : Northwestern University

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Chicago : University of Chicago Medical Center

Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer

Chicago : University of Chicago Comprehensive Cancer Center

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Chicago : Northwestern University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Evanston : Northshore University Health Systems Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Skokie : Edward H. Kaplan, MD and Associates Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Indiana

Goshen : Goshen Center for Cancer Care

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Indianapolis : Investigative Clinical Research of Indiana, LLC Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Indianapolis : Indiana University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Iowa

Iowa City : University of Iowa Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Kansas

Overland Park : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Wichita : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Westwood : University of Kansas Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Kentucky

Crestview Hills : Oncology Hematology Care, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Louisville : James Graham Brown Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Louisville : University of Louisville Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Louisiana

Baton Rouge : Mary Bird Perkins Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

New Orleans : Ochsner Cancer Institute Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Maryland

Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Baltimore : University of Maryland Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Bethesda : National Cacner Institue

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Massachusetts

Boston : Massachusetts General Hospital Dept. of Mass General Hospital

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Boston : Beth Israel Deaconess Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Boston : Massachusetts General Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Boston : Dana-Farber Cancer Institute Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

View More »

Burlington : Lahey Clinic Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Michigan

Ann Arbor : University of Michigan Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Detroit : Henry Ford Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Detroit : Karmanos Cancer Institute

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Grand Rapids : St. Mary's Trinity Healthcare

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

View More »

Kalamazoo : West Michigan Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Royal Oak : Beaumont Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Southfield : Providence Cancer Center Oncology and Hematology Care Clinic-Eastside Portland

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Minnesota

Minneapolis : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Minneapolis : Virginia Piper Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Minneapolis : Virginia Piper Cancer Institute Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Rochester : Mayo Clinic Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Mississippi

Tupelo : Hematology and Oncology Associates at BridgePoint

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Missouri

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Columbia : University of Missouri Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Saint Joseph : Saint Joseph Oncology, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Saint Louis : Washington University School of Medicine

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

View More »

Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

St. Louis : Washington University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Montana

Missoula : Montana Cancer Institute Foundation c/o Montana Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Nebraska

Omaha : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Omaha : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Omaha : University of Nebraska Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Nevada

Henderson : Comprehensive Cancer Centers of Nevada

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

New Mexico

Albuquerque : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Albuquerque : New Mexico Cancer Care Alliance

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Albuquerque : University of New Mexico Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

New York

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

A Phase 2 Study of REOLYSIN in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Bronx : Biomedical Research Alliance of New York

Pancreatic Cancer - Adults

Lake Success : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Lake Success : Biomedical Research Alliance of New York

Pancreatic Cancer

Syracuse : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

New York : Beth Israel Comprehensive Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

New York : Saint Luke's-Roosevelt Hospital Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

New York : Memorial Sloan Kettering Cancer Center MSKCC - SC

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

New York : Mount Sinai Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

New York : Memorial Sloan Kettering Cancer Center

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

North Carolina

Charlotte : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Durham : Duke University Medical Center, Comprehensive Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Durham : Duke University Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

High Point : Emerywood Hematology and Oncology

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Winston-Salem : Wake Forest Baptist Health Comprehensive Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Ohio

Blue Ash : Oncology Hematology Care, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Cincinnati : University of Cincinnati Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Cleveland : University Hospitals Case Western Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Cleveland : University Hospitals

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Columbus : Ohio State University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Oklahoma

Oklahoma City : University of Oklahoma Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Oregon

Portland : Oregon Health and Science University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pennsylvania

Bethlehem : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Philadelphia : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Pittsburgh : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Bethlehem : St. Luke's Hospital and Health Network Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Harrisburg : PinnacleHealth

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Hershey : Penn State Hershey Cancer Institute Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Philadelphia : Kimmel Cancer Center at Jefferson University

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Philadelphia : Fox Chase Cancer Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Philadelphia : Thomas Jefferson University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Philadelphia : University of Pennsylvania Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Pittsburg : University of Pittsburg Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pittsburgh : Hillman Cancer Center

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Willow Grove : Abington Hematology Oncology Associates, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Rhode Island

Providence : Roger Williams Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

South Carolina

Charleston : Charleston Hematology Oncology Associates, PA

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Columbia : South Carolina Oncology Associates

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Greenville : Institute of Translational Oncology Research

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Greenville : Cancer Center of the Carolinas Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Tennessee

Knoxville : Tennessee Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Nashville : Tennessee Oncology, PLLC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Texas

San Antonio : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Corpus Christi : Coastal Bend Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Dallas : University of Texas Southwestern Medical Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Fort Worth : Center for Cancer and Blood Disorders, PC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Houston : UT MD Anderson Cancer Center

Chemoradiation-Induced Nausea and Emesis: Quality of Life

Houston : Baylor College of Medicine Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Houston : Ben Taub Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Houston : The Methodist Hospital Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Lubbock : Joe Arrington Cancer Research and Treatment Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Lubbock : Joe Arrington Cancer Research and Treatment Center Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

San Antonio : University of Texas Health Sciences Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Utah

Salt Lake City : Utah Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman UT

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Virginia

Charlottesville : University of Virginia Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Fairfax : Virginia Cancer Specialists, PC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Lynchburg : Lynchburg Hematology-Oncology Clinic, Inc. Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Norfolk : VA Oncology Associates

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Richmond : Virginia Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

View More »

Richmond : Virginia Commonwealth University Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Washington

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Seattle : Virginia Mason Medical Center

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Seattle : Virginia Piper Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Seattle : University of Washington- Seattle Cancer Center Alliance Updated

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

West Virginia

Morgantown : West Virginia University - Clinical Trials Research Unit

ACOSOG-Z5041: Ph2 of Neoadjuvant and Adjuvant Gemcitabine Hydrochloride and Erlotinib Hydrochloride in pts + Resectable Adenocarcinoma of the Pancreas Undergoing Pancreatectomy.

Wisconsin

Australia

Blacktown : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Footscray : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Frankston, VIC : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Liverpool : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Parkville : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Tweed Heads : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Adelaide : Royal Adelaide Hospital

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Box Hill : Box Hill Hospital

A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Camperdown : Royal Prince Alfred Hospital

A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Heidelberg : The Austin Hospital

A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Nedlands : Sir Charles Gairdner Hospital and University of Western Australia

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Woodville South : The Queen Elizabeth Hospital

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Austria

Graz : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Innsbruck : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Wien : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Wien :

ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

Belgium

Brussels : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Gent : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Leuven : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Antwerp : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Canada

Montreal : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Montreal : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Quebec : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Toronto : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Calgary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

China

Shanghai : Shanghai Changhai Hospital

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Tianjin : Tianjin Medical University Cancer Institute and Hospital

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Cyprus

Nicosia : Cyprus Oncology Centre

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Czech Republic

Olomouc : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Pardubice : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Prague 8 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Zlin : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

France

Angers : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Besançon cedex : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Clermont Ferrand cedex 1 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Clichy : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Lille : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Lyon cedex 03 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Paris cedex 14 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Saint-Priest-en-Jarez : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Saint-Priest-en-Jarez cedex 2 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Clermont-Ferrand : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Lomme : Hôpital Saint-Philibert

Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas

Lyon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Lyon : Hôpital Jean Mermoz

Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas

Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Marseille : Institut Paoli Calmettes

Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas

Germany

Bochum : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Hamburg : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Hamburg : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Jena : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Köln : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Köln : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Lemgo : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Mannheim : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

München : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Tübingen : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Friedrichshafen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Leipzig : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Marburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Reutlingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Saarbrucken : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Hungary

Budapest : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Budapest : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Gyor : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Pecs : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Ireland

Dublin 24 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Dublin 4 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Dublin 7 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Dublin 9 : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Israel

Beer Sheva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Jerusalem : Hadassah Medical Organization

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas

Jerusalem : Shaare Zedek Medical Center

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas

Petah Tiqva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

View More »

Ramat Gan : Sheba Medical Center

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas

Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Italy

Ancona : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Bologna : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Chieti : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Milan : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Reggio Emilia : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Udine : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Bologna : Azienda Ospedaliero-Universitaria di Bologna

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Confreria : A.O. Santa Croce e Carle, Struttura Complessa di Oncologia Medica

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Monza : Azienda Ospedaliera San Gerardo Struttura Complessa Oncologia Medica

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Novara : AOU Maggiore della Carità

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Verona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Japan

Gifu : Gifu University

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Onomichi : Onomichi General Hospital

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Sapporo : Teine-Keijinkai Hospital

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Tokyo : The University of Tokyo

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Tokyo : Toho University

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

View More »

Tokyo : Tokyo Medical University

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Ube : Yamaguchi University

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Korea, Republic of

Bucheon : Soon Chun Hyang University School of Medicine

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Cheonan : Soon Chun Hyang University School of Medicine

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Daegu : Catholic University of Daegu School of Medicine

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Goyang-si : NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,

Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)

Incheon : Inha University School of Medicine

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

View More »

Seoul : Gangnam Severance Hospital

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Suwon : Ajou University School of Medicine

Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Netherlands

Amsterdam : VU University Medical Center

Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

New Zealand

Christchurch : Christchurch Hospital

A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Hamilton : Waikato Hospital

A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Norway

Poland

Jelenia Gora : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Lublin : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Olsztyn : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Romania

Bucharest : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Cluj-Napoca : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Craiova : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

IASI : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Russia

Chelyabinsk : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Kazan : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Krasnodar : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Moscow : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Voronezh : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Saudi Arabia

Riyadh : National Guard Health Affairs

Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer

Singapore

Outram Road : Singapore General Hospital

32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer

Spain

Alicante : Hospital General de Alicante

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Asturias : Medical Oncology Department, Central University Hospital of Asturias

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Barcelona : Novartis Investigative Site

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

View More »

Madrid : START Madrid

A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Madrid : Hospital Gregorio Marañon

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Pozuelo De Alarcon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Valencia : Department of Medical Oncology, Hospital Universitari La Fe,

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Valencia : Instituto Valenciano de Oncologia

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Zaragoza : Hospital Miguel Servet

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

United Kingdom

Chelmsford, Essex : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Edinburgh : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Glasgow : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Hull : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Leeds : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Liverpool : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

London : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

London : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Maidstone : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Northwood : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Salisbury : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Sutton : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

View More »

Blackburn : Royal Blackburn Hospital

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Bournemouth : The Royal Bournemouth Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Bradford : Bradford Royal Infirmary

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Cambridge : Cambridge University Hospitals NHS Foundation Trust

HYPAZ: Hypertension Induced by Pazopanib

Cardiff : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Cardiff : Velindre Cancer Centre

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Dundee : Ninewells Hospital,

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Edinburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Guildford : Royal Surrey County Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Liverpool : Clatterbridge Centre for Oncology

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Liverpool : Royal Liverpool University Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Liverpool : Novartis Investigative Site

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

London : Guy's and St Thomas' Hospital NHS Trust

32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer

London : The London Clinic Cancer Centre

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

London : Mount Vernon Cancer Centre

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

London : Guys & St Thomas Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Manchester : The Christie Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Middlesbrough : James Cook University Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Nottingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Nottingham : Nottingham City Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Peterborough : Peterbrough City Hospital, Haematology/Oncology Dept,

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Sheffield : Weston Park Hospital

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Skipton : Airedale General Hospital

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Southampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Sutton : The Royal Marsden NHS Trust

A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)

USA

Liverpool : Research Site

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)